Madrigal制药公司授权六个临床前siRNA项目以扩展NASH管线Madrigal Pharmaceuticals Licenses Six Preclinical siRNA Programs to Expand NASH Pipeline

动脉网02-11

by GOAI由GOAI生成Share To分享到Madrigal Pharmaceuticals has entered into an exclusive global licensing agreement to expand its MASH (Metabolic Associated Steatohepatitis) pipeline. The agreement includes ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2610024939?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-11 19:13","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2610024939","market":"us","top_or_hot":-1,"title":"Madrigal制药公司授权六个临床前siRNA项目以扩展NASH管线Madrigal Pharmaceuticals Licenses Six Preclinical siRNA Programs to Expand NASH Pipeline","media":"动脉网","content":"<div>\n<p>by GOAI由GOAI生成Share To分享到Madrigal Pharmaceuticals has entered into an exclusive global licensing agreement to expand its MASH (Metabolic Associated Steatohepatitis) pipeline. The agreement includes ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211191520a6eec729&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Madrigal制药公司授权六个临床前siRNA项目以扩展NASH管线Madrigal Pharmaceuticals Licenses Six Preclinical siRNA Programs to Expand NASH Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMadrigal制药公司授权六个临床前siRNA项目以扩展NASH管线Madrigal Pharmaceuticals Licenses Six Preclinical siRNA Programs to Expand NASH Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-11 19:13 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211191520a6eec729&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>by GOAI由GOAI生成Share To分享到Madrigal Pharmaceuticals has entered into an exclusive global licensing agreement to expand its MASH (Metabolic Associated Steatohepatitis) pipeline. The agreement includes ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211191520a6eec729&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211191520a6eec729&s=b","article_id":"2610024939","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211191520a6eec729&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610024939","pubTimestamp":1770808380,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"by GOAI由GOAI生成Share To分享到Madrigal Pharmaceuticals has entered into an exclusive global licensing agreement to expand its MASH  pipeline. The agreement includes six preclinical siRNA  programs, which aim to address various aspects of liver disease and metabolic disorders.Madrigal Pharmaceuticals 已达成一项独家全球许可协议，以扩展其 MASH产品线。该协议包括六个临床前的 siRNA项目，旨在解决肝脏疾病和代谢紊乱的各个方面。The licensing deal grants Madrigal access to these six siRNA programs, which are currently in the preclinical stage. These programs focus on utilizing RNA interference technology to target specific pathways associated with liver diseases and metabolic dysfunctions. The company plans to integrate these programs into its existing pipeline for further development and potential clinical trials.该许可协议授予麦德rigal公司访问这六个siRNA项目，这些项目目前处于临床前阶段。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","MDGL":"Madrigal Pharmaceuticals, Inc.","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"Madrigal Pharmaceuticals Authorizes Six Preclinical siRNA Programs to Expand NASH Pipeline Madrigal Pharmaceuticals Licenses Six Preclinical siRNA Programs to Expand NASH Pipeline","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":0.9},"content_text":"by GOAI由GOAI生成Share To分享到Madrigal Pharmaceuticals has entered into an exclusive global licensing agreement to expand its MASH (Metabolic Associated Steatohepatitis) pipeline. The agreement includes six preclinical siRNA (small interfering RNA) programs, which aim to address various aspects of liver disease and metabolic disorders.Madrigal Pharmaceuticals 已达成一项独家全球许可协议，以扩展其 MASH（代谢相关脂肪性肝炎）产品线。该协议包括六个临床前的 siRNA（小干扰 RNA）项目，旨在解决肝脏疾病和代谢紊乱的各个方面。This development marks a significant addition to Madrigal’s research portfolio in the field of NASH (Nonalcoholic Steatohepatitis)..这一进展标志着Madrigal在NASH（非酒精性脂肪性肝炎）领域的研究组合中增加了重要的一部分。The licensing deal grants Madrigal access to these six siRNA programs, which are currently in the preclinical stage. These programs focus on utilizing RNA interference technology to target specific pathways associated with liver diseases and metabolic dysfunctions. The company plans to integrate these programs into its existing pipeline for further development and potential clinical trials.该许可协议授予麦德rigal公司访问这六个siRNA项目，这些项目目前处于临床前阶段。这些项目专注于利用RNA干扰技术靶向与肝脏疾病和代谢功能障碍相关的特定通路。该公司计划将这些项目整合到其现有研发管线中，以进行进一步开发和潜在的临床试验。Details regarding the financial terms of the agreement or the timeline for advancing these programs have not been disclosed at this time..目前尚未披露有关该协议的财务条款或推进这些计划的时间表的细节。Newsflash | Powered by GeneOnline AI新闻快讯 | 由GeneOnline AI提供支持Source: GO-AI-ne1来源：GO-AI-ne1For any suggestion and feedback, please contact us.如果有任何建议和反馈，请联系我们。Date: The formatted date is: February 11, 2026日期：格式化的日期为：2026年2月11日©www.geneonline.com All rights reserved. Collaborate with us:©www.geneonline.com 保留所有权利。与我们合作：[email protected]电子邮件地址Author作者GOAIGOAIRelated Post相关文章","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610024939","isCrawlerRequest":true}